SHPG

Shire Shs Sponsored American Deposit Receipt Repr 3 Shs

Healthcare


Presented:02/22/2017
Price:$181.00
Cap:$54.97B
Current Price:$160.79
Cap:$49.20B

Presented

Date02/22/2017
Price$181.00
Market Cap$54.97B
Ent Value$74.39B
P/E Ratio119.19x
Book Value$97.17
Div Yield0%
Shares O/S303.70M
Ave Daily Vol1,064,058
Short IntN/A

Current

Price$160.79
Market Cap$49.20B
Shire Plc is a biopharmaceutical company, which focuses on developing and marketing innovative medicines for patients with rare diseases and other conditions. It engaged in the research, development, licensing, manufacturing, marketing, distribution and sale of innovative specialist medicines to meet significant unmet patient needs. The company was founded in 1986 and is headquartered in Dublin, Ireland.

Publicly traded companies mentioned herein: Allergan Inc (AGN), Bioverativ Inc (BIVV), Roche Holding Ltd (RHHBY), Shire PLC (SHPG)

Highlights

The presenter is long Shire (SHPG) at $183 and thinks shareholders will see gains “if the company can just hit numbers” near-term. He likes CEO Flemming Ornskov and the company’s focus on rare diseases; and said he expects to see “at least” mid-to-high single digit (%) revenue growth and mid-to-high teens (%) earnings growth over the next two years. The market is overly negative on hemophilia, in his opinion, and synergy guidance for the Baxalta integration appears to be conservative at $700 million. Shire should be able to pay down debt rapidly, and with the stock trading at a discount to the peer group he is comfortable being long and waiting to see if a) Xiidra sales can exceed expectations; b) SHP643 (formerly DX 2930) can deliver in HAE (Phase 3 data is expected in Q2 2017); and c) SHP465 will be approved for treatment of ADHD (PDUFA date is June 20, 2017).

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Request access to DeMatteo Research for full access

Request Access

Already have an account?

Idea Discussion

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Idea Discussions display submitted commentary from our investor community.

To read and participate in the discussion with the presenter and investor base, request access to DeMatteo

Request Access

Already have an account?

An error occurred loading this content. Try again later or contact us.